Literature DB >> 18602369

Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells.

Kazuo Kamemura1, Akihiro Ito, Tadahiro Shimazu, Akihisa Matsuyama, Satoko Maeda, Tso-Pang Yao, Sueharu Horinouchi, Saadi Khochbin, Minoru Yoshida.   

Abstract

Histone deacetylase 6 (HDAC6) is a multifunctional, cytosolic protein deacetylase that primarily acts on alpha-tubulin. Here we report that stable knockdown of HDAC6 expression causes a decrease in the steady-state level of receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor alpha, in A549 lung cancer cells. The decreased levels of in EGFR in HDAC6-knockdown cells, which correlated with increased acetylation of microtubules, were due to increased turnover of EGFR protein. Despite the decrease in EGFR levels, A549 cells lacking functional HDAC6 appeared to grow normally, probably due to increased expression of extracellular signal-regulated kinases 1 and 2. Indeed, HDAC6-knockdown cells were more sensitive than control cells to the MEK inhibitor U0126. These results suggest that HDAC6 inhibitors combined with inhibitors of growth factor signaling may be useful as cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602369     DOI: 10.1016/j.bbrc.2008.06.092

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Epigenetics and autosomal dominant polycystic kidney disease.

Authors:  Xiaogang Li
Journal:  Biochim Biophys Acta       Date:  2010-10-20

2.  Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors.

Authors:  Hui Song; Chia-Wei Li; Adam M Labaff; Seung-Oe Lim; Long-Yuan Li; Shu-Fen Kan; Yue Chen; Kai Zhang; Jingyu Lang; Xiaoming Xie; Yan Wang; Long-Fei Huo; Sheng-Chieh Hsu; Xiaomin Chen; Yingming Zhao; Mien-Chie Hung
Journal:  Biochem Biophys Res Commun       Date:  2010-11-19       Impact factor: 3.575

3.  The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation.

Authors:  Ya-sheng Gao; Charlotte C Hubbert; Tso-Pang Yao
Journal:  J Biol Chem       Date:  2010-02-04       Impact factor: 5.157

4.  Effect of EGF-induced HDAC6 activation on corneal epithelial wound healing.

Authors:  Jie Wang; Andrew Lin; Luo Lu
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

5.  Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.

Authors:  Benoît Busser; Lucie Sancey; Véronique Josserand; Carole Niang; Saadi Khochbin; Marie C Favrot; Jean-Luc Coll; Amandine Hurbin
Journal:  Mol Ther       Date:  2009-10-13       Impact factor: 11.454

6.  Histone deacetylase 6 (HDAC6) is an essential factor for oocyte maturation and asymmetric division in mice.

Authors:  Dongjie Zhou; Yun-Jung Choi; Jin-Hoi Kim
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

7.  HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells.

Authors:  Wei Liu; Lucy X Fan; Xia Zhou; William E Sweeney; Ellis D Avner; Xiaogang Li
Journal:  PLoS One       Date:  2012-11-13       Impact factor: 3.240

8.  Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells.

Authors:  Lei Wang; Shengyan Xiang; Kendra A Williams; Huiqin Dong; Wenlong Bai; Santo V Nicosia; Saadi Khochbin; Gerold Bepler; Xiaohong Zhang
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

9.  Nuclear HDAC6 inhibits invasion by suppressing NF-κB/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.

Authors:  Chih-Jen Yang; Yu-Peng Liu; Hong-Ying Dai; Yow-Ling Shiue; Chia-Jung Tsai; Ming-Shyan Huang; Yao-Tsung Yeh
Journal:  Oncotarget       Date:  2015-10-06

10.  HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

Authors:  Teru Hideshima; Ralph Mazitschek; Jun Qi; Naoya Mimura; Jen-Chieh Tseng; Andrew L Kung; James E Bradner; Kenneth C Anderson
Journal:  Oncotarget       Date:  2017-07-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.